Compare AXON & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXON | NTRA |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2B | 28.2B |
| IPO Year | 2001 | 2015 |
| Metric | AXON | NTRA |
|---|---|---|
| Price | $389.90 | $203.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | ★ $758.80 | $259.07 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $2,779,536,000.00 | $210,939,000.00 |
| Revenue This Year | $31.50 | $18.08 |
| Revenue Next Year | $28.95 | $19.65 |
| P/E Ratio | $191.21 | ★ N/A |
| Revenue Growth | ★ 33.47 | N/A |
| 52 Week Low | $339.01 | $131.81 |
| 52 Week High | $885.92 | $256.36 |
| Indicator | AXON | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 50.89 |
| Support Level | $371.14 | $186.96 |
| Resistance Level | $426.59 | $204.34 |
| Average True Range (ATR) | 24.73 | 10.78 |
| MACD | 1.51 | 0.10 |
| Stochastic Oscillator | 32.62 | 49.78 |
Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions. The company's suite includes cloud-hosted digital evidence management solutions, TASER energy devices, drones and robotic security, and training solutions. Its operation comprises of two operating segments, Software and Services, and Connected Devices. The company generates the majority of its revenue from the Connected Devices segment, which is engaged in developing, manufacturing, and selling fully integrated hardware solutions such as conducted energy devices sold under the TASER brand, body cameras, fixed and in-car cameras, drone and counter-drone technologies, and a broad ecosystem of accessories, extended warranties and related hardware products.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.